Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | AOC2 | O75106 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24113076 | 1.00 | HTT (0.46) | HTTHPGDALDH1A1HRH3TSHR | |
| SCHEMBL31061821 | 1.00 | HTT (0.46) | HTTHPGDALDH1A1HRH3TSHR | |
| SCHEMBL17761374 | 0.85 | HRH3 (0.43) | HTTHPGDHRH3TSHRGPBAR1 | |
| SCHEMBL16428909 | 0.83 | CA2 (0.54) | — | |
| SCHEMBL407496 | 0.83 | CA2 (0.54) | — | |
| SCHEMBL11451572 | 0.83 | HTT (0.38) | HTTHPGDALDH1A1HRH3TSHR | |
| SCHEMBL4522017 | 0.83 | HTT (0.63) | HTTHPGDALDH1A1HRH3TSHR | |
| SCHEMBL15211143 | 0.83 | CA2 (0.54) | — | |
| Bicarbonate SCHEMBL8124381 | 0.81 | GPBAR1 (0.44) | HTTHPGDALDH1A1HRH3TSHR | |
| Bicarbonate SCHEMBL8116427 | 0.81 | GPBAR1 (0.44) | HTTHPGDALDH1A1HRH3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3902798-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | Endogena Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113227086-A | N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal diseases | 内生疗法公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-10246470-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2019-04-02 | — | — | US | disclosed |
| US-20180346486-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2018-12-06 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| EP-3068788-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Cadila Healthcare Limited (IN) | 2016-09-21 | — | — | EP | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| CN-105722841-A | Novel Heterocyclic Compounds | 卡迪拉保健有限公司 | 2016-06-29 | — | — | CN | disclosed |
| WO-2015097713-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2015-07-02 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4720559-A | Certain 2,3-dihydobenzofuran-3-yl acetic acids and their method of preparation | EASTMAN KODAK COMPANY (US) | 1988-01-19 | — | — | US | disclosed |
| US-4129655-A | Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans | CIBA-GEIGY CORPORATION (US) | 1978-12-12 | — | — | US | disclosed |
| US-4104396-A | NEUROLEPTIC, ANALGESIC | CIBA-GEIGY CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
| US-4039676-A | NEUROLEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011609-B2 | Heterocyclic compounds | GPR55, GPR68, GPR65 | HTT 1215/4885HPGD 845/4885ALDH1A1 1896/4885 |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | NR2E3, GFRA2, ALDH1A2 | HTT 3177/4885HPGD 2262/4885ALDH1A1 1885/4885 |
| US-20180346486-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HK1, HAAO, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTT 425/4885HPGD 541/4885ALDH1A1 478/4885 |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | NR2E3, GFRA2, ALDH1A2 | HTT 3177/4885HPGD 2262/4885ALDH1A1 1885/4885 |
| US-10246470-B2 | Heterocyclic compounds | HAAO, HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTT 136/4885HPGD 411/4885ALDH1A1 576/4885 |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GPR55, GPR68, GPR65 | HTT 1669/4885HPGD 1056/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.